ASX:WDS
ASX:WDSOil and Gas

Assessing Woodside Energy Group (ASX:WDS) Valuation After Recent Share Price Momentum

Woodside Energy Group (ASX:WDS) is back on many investors’ screens after recent share price moves, with the stock last closing at A$24.02 and mixed return figures across different time frames. See our latest analysis for Woodside Energy Group. The recent 7 day share price return of 4.66% and 90 day share price return of 8.69% suggest some momentum is building. However, the 1 year total shareholder return of a 0.61% decline and 3 year total shareholder return of an 18% decline point to a...
ASX:PNR
ASX:PNRMetals and Mining

Pantoro Gold ASX PNR Valuation Check After High Grade Norseman Drilling Results

Event driven interest in Pantoro Gold Pantoro Gold (ASX:PNR) has caught investor attention after reporting high grade drilling results at the Daisy South deposit within its 100% owned Norseman Gold Project in Western Australia. The results confirm extensions to existing mineralisation and support plans for a new open pit that is intended to run alongside current operations, with mine scheduling aligned to the Gladstone Everlasting Open Pit. See our latest analysis for Pantoro Gold. After...
ASX:NTU
ASX:NTUMetals and Mining

Is Northern Minerals' (ASX:NTU) Concentrated Register Quietly Reshaping Its Long-Dated Project Strategy?

Recent coverage has highlighted how ownership concentration and broad shareholder participation at Northern Minerals is shaping governance and strategic influence in its long‑dated mining projects. This focus on who holds power in the register offers investors a clearer view of how decisions may be made and aligned across stakeholders. Next, we examine how this growing interest in Northern Minerals’ ownership structure could influence the company’s broader investment narrative. Uncover the...
ASX:IPX
ASX:IPXMetals and Mining

Assessing IperionX’s Valuation After New US$99m Defense Contract And Titanium Campus Commissioning

What triggered the latest move in IperionX? IperionX (ASX:IPX) is back on investor radars after securing a U.S. Department of Defense contract valued at up to US$99 million, tied to domestic titanium production for defense uses. See our latest analysis for IperionX. The stock’s recent move sits within a mixed backdrop, with a 1 month share price return of 40.36% and a year to date share price return of 20.73%. The 1 year total shareholder return of 58.14% and very large 5 year total...
ASX:TEA
ASX:TEAConstruction

Tasmea (ASX:TEA) Valuation Check After Governance Update On Equity Incentive Structure

Tasmea (ASX:TEA) is back on investors’ radars after a fresh update on its equity-based staff incentives, which puts governance transparency and capital consistency at the center of the story. See our latest analysis for Tasmea. The update on equity incentives comes as Tasmea’s 1 day share price return of 2.93% and 7 day share price return of 10.68% sit against a year to date share price return of 8.83% and a 1 year total shareholder return of 63.41%. Together, these figures point to momentum...
ASX:COH
ASX:COHMedical Equipment

Cochlear’s VA Nexa Rollout Sparks Fresh Look At Whether The Shares Are Undervalued

Cochlear’s VA access expansion and what it might mean for shareholders Cochlear (ASX:COH) recently made its Nucleus Nexa cochlear implant system available to eligible US military veterans at VA clinics nationwide, a move that widens access and puts a spotlight on its hearing technology offering. See our latest analysis for Cochlear. The Nucleus Nexa news comes after a period where short term share price momentum has softened. A 90 day share price return of a 6.38% decline contrasts with a 5...
ASX:CUV
ASX:CUVBiotechs

Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential

Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing. See our latest analysis for Clinuvel Pharmaceuticals. The VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...
ASX:HCH
ASX:HCHMetals and Mining

Does Hot Chili (ASX:HCH)'s Cortadera Funding Plan Clarify Its Long-Term Development Strategy?

Hot Chili Limited recently released an earnings update that underscored ongoing exploration-stage losses and heightened uncertainty around funding and development of its Cortadera copper-gold project in Chile. The update sharpened market focus on how management plans to sequence project milestones, secure capital, and manage permitting risk at Cortadera. We will now examine how Hot Chili’s funding approach for Cortadera shapes the company’s investment narrative and future project...
ASX:GGP
ASX:GGPMetals and Mining

Is Greatland Resources (ASX:GGP) Turning Rising Output Into a More Durable Operating Story?

In January 2026, Greatland Resources Limited reported preliminary operating results for the December 2025 quarter, delivering production of 86,273 oz of gold and 3,528 tonnes of copper, up from the prior quarter and bringing first-half FY2026 output to 167,163 oz of gold and 6,894 tonnes of copper. This steady lift in quarterly production offers fresh insight into how Greatland Resources is converting its asset base into higher operational throughput. With production volumes rising...
ASX:CYL
ASX:CYLMetals and Mining

Stronger Quarterly Gold Output Could Be A Game Changer For Catalyst Metals (ASX:CYL)

Catalyst Metals recently reported an upbeat quarterly gold production update, highlighting stronger operational output across its Australian-focused gold projects. This production improvement underlines how operational delivery is becoming a more prominent driver of investor interest for the mineral explorer. Next, we will examine how this stronger quarterly gold production shapes Catalyst Metals’ broader investment narrative and future positioning. Trump's oil boom is here - pipelines are...
ASX:TWE
ASX:TWEBeverage

Assessing Treasury Wine Estates' Valuation As Weaker Wine Demand Meets A$100 Million Cost Cuts

Treasury Wine Estates (ASX:TWE) has returned to focus after updating investors on weaker global wine demand, softer conditions in key markets such as the US and China, and a company wide cost cutting program targeting about A$100 million in annual savings. See our latest analysis for Treasury Wine Estates. The recent company update on weaker global wine demand and the A$100 million cost cutting plan comes after a 90 day share price return decline of 14.51% and a 1 year total shareholder...
ASX:DMP
ASX:DMPHospitality

Assessing Domino's Pizza Enterprises (ASX:DMP) Valuation After New Leadership Appointments And Turnaround Focus

Domino's Pizza Enterprises (ASX:DMP) has refreshed its senior ranks, appointing Merrill Pereyra as CEO for Australia and New Zealand and expanding CFO George Saoud’s remit to include Group Chief Operating Officer responsibilities. See our latest analysis for Domino's Pizza Enterprises. The leadership reshuffle comes after a strong 90 day share price return of 53.43% to A$23.26. However, the 1 year total shareholder return of 18.29% and 5 year total shareholder return of 70.69% point to longer...
ASX:XRO
ASX:XROSoftware

Assessing Xero’s Valuation As New AI Analytics And JAX Push Its Small Business Platform Forward

Xero (ASX:XRO) has launched new AI powered analytics globally, building on its 2024 Syft acquisition to embed dashboards, cash flow tools, and AI driven financial insights directly into its small business accounting platform. See our latest analysis for Xero. Despite the launch of its AI analytics and earlier announcements such as JAX, Xero’s 90 day share price return of 30.49% and 1 year total shareholder return of 35.02% both sit in negative territory. The 3 year total shareholder return of...
ASX:DYL
ASX:DYLOil and Gas

Assessing Deep Yellow (ASX:DYL) Valuation After The Upcoming CEO And Managing Director Transition

Deep Yellow (ASX:DYL) has announced that Greg Field will take over as Chief Executive Officer and Managing Director from February 2, 2026. This leadership shift could influence how investors assess the uranium explorer. See our latest analysis for Deep Yellow. The leadership announcement comes after a mixed stretch for Deep Yellow, with a 14.69% 1 month share price return contrasting with a 17.48% 3 month share price decline. The 1 year total shareholder return of 61.75% points to longer term...
ASX:29M
ASX:29MMetals and Mining

Assessing 29Metals (ASX:29M) Valuation After Jefferies Downgrade And Operational Setbacks

Jefferies’ downgrade of 29Metals (ASX:29M) to Underperform after a strong share price rally, tied to an 86% zinc production shortfall from seismic issues at the Xantho Extended mine, has sharpened investor focus on operational risk. See our latest analysis for 29Metals. The recent downgrade comes after a strong run, with a 30 day share price return of 43.82% and a 1 year total shareholder return of 197.67%, while the 3 year total shareholder return is 65.81% lower. This suggests that shorter...
ASX:SFR
ASX:SFRMetals and Mining

Assessing Sandfire Resources (ASX:SFR) Valuation After New 2026 Production Guidance And Copper Demand Tailwinds

Why Sandfire’s fresh guidance is drawing attention Sandfire Resources (ASX:SFR) has put fresh numbers around its 2026 outlook, issuing production guidance across copper, zinc, lead and silver at the same time as investors focus closely on global copper demand. See our latest analysis for Sandfire Resources. The guidance comes after a strong run in the share price, with a 30 day share price return of 13.18% and a 90 day share price return of 20.93%. The 1 year total shareholder return of...
ASX:PFP
ASX:PFPConsumer Services

3 ASX Penny Stocks With Market Caps Under A$2B To Watch

As Australian shares ride the wave of rising commodity prices, with gold, silver, and copper reaching new highs, investors are keenly watching how these trends might influence broader market dynamics. Amid this backdrop, penny stocks—often smaller or newer companies—continue to offer intriguing opportunities for those looking beyond the mainstream. Despite being considered a niche area of investment today, these stocks can still present significant growth potential when backed by strong...
ASX:MSB
ASX:MSBBiotechs

Does Mesoblast’s New Board Leadership After First FDA Approval Change The Bull Case For ASX:MSB?

In early January 2026, Mesoblast Limited implemented a series of board changes, appointing Philip Facchina as non-executive Chair and Lyn Cobley as Chair of the Audit and Risk Committee, while former Chair Jane Bell retired from that role but remained on the board. These governance shifts come as Mesoblast moves further into a revenue-generating commercial phase following its first U.S. FDA approval, highlighting an effort to align board oversight with the company’s next stage of corporate...